Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 256 in Advanced Solid Tumors
NCT04362748Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of anti-PD-1 mAb3 × R9E:R76A in solid tumor (3 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities and Treatment-emergent Adverse Events. Started Sep 2020; status: completed.
02
Drugs
anti-PD-1 mAb3 × R9E:R76A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04362748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362748.